Vivex Biomedical raises $6.6m in Series A

Vivex Biomedical reported it pulled in $6.6 million in a Series A equity round of convertible preferred stock, according to an SEC filing.

The company is focused on cellular therapies for treating orthopedic, spinal, wound and soft tissue indications, according to its website.

Marietta, Ga.-based Vivex Biomedical develops a number of regenerative medical products, including amniotic membrane patches for wound healing, biocompatible particulates for spinal fusions and other procedures, and radioopaque calcium phosphate synthetic bone grafts.

Vivex is headed by CEO Tracy Anderson, who founded spinal device company T2Med, which was merged with Amendia in 2008.

The company is still looking for another $3.4 million before closing the round, according to an SEC filing. The current funds came from 42 unnamed investors, and Vivex has not yet said how it plans to use the funds.

The post Vivex Biomedical raises $6.6m in Series A appeared first on MassDevice.

from MassDevice http://ift.tt/1TD4VRO